Angiotensin II vs Adrenomedullin

Angiotensin II and Adrenomedullin exemplify two contrasting facets of vasoactive peptides in research. Angiotensin II is a key player in the renin-angiotensin-aldosterone system (RAAS), recognized for its role as a potent vasoconstrictor with established therapeutic applications in managing vasodilatory shock. In contrast, Adrenomedullin, a 52-amino-acid peptide, is primarily investigated for its vasodilatory, natriuretic, and cardioprotective properties, and is emerging as a promising prognostic biomarker in critical conditions like sepsis and heart failure. This comparison will explore their mechanisms of action, the robustness of clinical evidence, dosing considerations, and safety profiles, outlining the critical distinctions and potential overlaps that researchers should consider when designing their studies.

Angiotensin II, an endogenous octapeptide (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe, MW ~1046.2 g/mol), serves as a principal effector in the RAAS. Its action is mediated through AT1 and AT2 receptors, leading to vasoconstriction, increased aldosterone secretion, and sodium retention. The synthetic formulation Giapreza has received FDA approval for use in adult patients experiencing vasodilatory shock, marking it as the only approved exogenous angiotensin II product for this purpose. The pivotal ATHOS-3 trial demonstrated significant efficacy in elevating blood pressure in patients resistant to catecholamines, facilitating a reduction in background vasopressor therapy. Notably, emerging research suggests a survival advantage in patients with elevated renin levels, indicating the potential for biomarker-guided therapeutic strategies. However, its clinical application is largely confined to critical care settings, with ongoing investigations into its use in conditions such as angiotensin-converting enzyme inhibitor overdose and hepatorenal syndrome.

Adrenomedullin is a 52-amino-acid peptide (MW ~6028 g/mol) initially identified in human pheochromocytoma tissue. It is expressed in various tissues, including the cardiovascular system, lungs, kidneys, and adrenal glands, where it exerts significant vasodilatory, natriuretic, and cardioprotective effects. This peptide acts primarily through the calcitonin receptor-like receptor (CRLR) in conjunction with receptor activity-modifying proteins (RAMPs). Unlike Angiotensin II, Adrenomedullin has not yet achieved therapeutic approval; however, its mid-regional fragment (MR-proADM) has gained attention as a prognostic biomarker in sepsis and acute heart failure, demonstrating strong predictive capabilities for mortality. Experimental studies involving intravenous infusion in healthy individuals have confirmed its vasodilatory effects, inducing dose-dependent hypotension and reflex tachycardia. Ongoing research is exploring its potential applications in conditions such as pulmonary hypertension and preeclampsia, yet its therapeutic development remains largely in the preclinical stage.

Despite their opposing hemodynamic profiles, Angiotensin II and Adrenomedullin share research applications in critical care settings, particularly in the contexts of sepsis and shock. Angiotensin II is investigated primarily as a vasopressor rescue therapy, while Adrenomedullin is explored for its role as a biomarker and potential modulator of vascular permeability. In cardiovascular research, Angiotensin II is studied in relation to hypertension and heart failure models, whereas Adrenomedullin is examined for its cardioprotective and natriuretic properties. Additionally, both peptides are relevant in renal physiology: Angiotensin II is crucial for regulating renal blood flow and sodium handling, while Adrenomedullin promotes diuresis and offers potential renoprotective benefits. Nonetheless, the applications of these peptides remain largely distinct, with Angiotensin II focusing on acute hemodynamic support and Adrenomedullin emphasizing biomarker development and exploration of its vasodilatory mechanisms.

In the ATHOS-3 trial, the use of Angiotensin II was associated with an increased incidence of thromboembolic events compared to placebo (12.9% vs 5.1%), highlighting the necessity for concurrent venous thromboembolism prophylaxis in clinical settings. Additionally, adverse effects such as tachyarrhythmias and peripheral ischemia, including digital ischemia, have been documented, particularly in critically ill patients with multiple comorbidities. Conversely, there is a lack of controlled human therapeutic safety data for Adrenomedullin. Experimental intravenous infusion in healthy volunteers has resulted in dose-dependent hypotension and reflex tachycardia, raising concerns regarding potential excessive vasodilation and hemodynamic instability. Preclinical studies suggest a favorable safety profile at lower doses; however, the translation of these findings to therapeutic contexts remains uncertain. Researchers should carefully consider these safety profiles when designing studies, especially in populations that may be particularly vulnerable.